A PHASE IB DOSE-ESCALATION TRIAL OF ISATUXIMAB (SAR650984, ANTI-CD38 MAB) PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): INTERIM RESULTS FROM 2 NEW DOSE COHORTS

被引：0
|
作者：
Lendvai, N. [1 ]
Vij, R.
Martin, T. G. [2 ]
Baz, R. [3 ]
Campana, F. [4 ]
Mazuir, F. [5 ]
Charpentier, E. [4 ]
Benson, D. M. [6 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] Sanofi Oncol, Cambridge, MA USA
[5] Sanofi Res & Dev, Alfortville, France
[6] Ohio State Univ, Columbus, OH 43210 USA
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P278
引用
收藏
页码：84 / 84
页数：1
相关论文
共 50 条
  • [21] MOR202 with low-dose dexamethasone (Dex) and in combination with pomalidomide/dex and lenalidomide/dex in relapsed or refractory multiple myeloma (RRMM): Interim analysis of a phase I/IIa dose-escalation study.
    Raab, Marc
    Chatterjee, Manik
    Goldschmidt, Hartmut
    Agis, Hermine
    Blau, Igor W.
    Einsele, Hermann
    Engelhardt, Monika Martha
    Ferstl, Barbara
    Gramatzki, Martin
    Rollig, Christoph
    Weisel, Katja C.
    Jarutat, Tiantom
    Weinelt, Dominika
    Winderlich, Mark
    Boxhammer, Rainer
    Peschel, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] GEN3014 (HexaBody ®-CD38) in Anti-CD38 Mab-Naive Patients with Relapsed/Refractory Multiple Myeloma: Preliminary Results from a Dose-Expansion Cohort of a Phase 1/2 Trial
    Grosicki, Sebastian
    Plesner, Torben
    Jurczak, Wojciech
    Radocha, Jakub
    Malek, Ehsan
    Hiemstra, Ida
    Brady, Lauren K.
    Chen, Jenny
    Gong, Nian
    Hindsberger, Charlotte
    Spencer, Andrew
    BLOOD, 2023, 142
  • [23] A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts
    Nadeem, Omar
    Mo, Clifton C.
    Laubach, Jacob P.
    Bianchi, Giada
    Redd, Robert
    Barth, Peter
    Bayliss, Trevor J.
    Sanchorawala, Vaishali
    Shune, Leyla
    Distaso, Alexandra
    Dalton, Virginia
    Sperling, Adam S.
    Amweg, Laura
    McKenney, Mary
    Colson, Kathleen
    Millard, Ella L.
    Hou, Isabella
    Savell, Alexandra
    Masone, Kelly
    Munshi, Nikhil C.
    Ghobrial, Irene M.
    Anderson, Kenneth
    Richardson, Paul G.
    BLOOD, 2020, 136
  • [24] PX-171-006: PHASE IB MULTICENTER DOSE ESCALATION STUDY OF CARFILZOMIB (CFZ) PLUS LENALIDOMIDE (LEN) AND LOW DOSE DEXAMETHASONE (LODEX) IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (MM) - PRELIMINARY RESULTS
    Wang, M.
    Gutierrez, A.
    Niesvizky, R.
    Bensinger, B.
    Vallone, M.
    Gutierrez, A. A.
    Kauffman, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 431 - 431
  • [25] MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study
    Raab, Marc S.
    Chatterjee, Manik
    Goldschmidt, Hartmut
    Agis, Hermine
    Blau, Igor
    Einsele, Hermann
    Engelhardt, Monika
    Ferstl, Barbara
    Gramatzki, Martin
    Rollig, Christoph
    Weisel, Katja
    Jarutat, Tiantom
    Weinelt, Dominika
    Winderlich, Mark
    Peschel, Christian
    BLOOD, 2018, 132
  • [26] PX-171-006: Phase Ib multicenter dose escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) and low-dose dexamethasone (loDex) in relapsed and refractory multiple myeloma (MM): Preliminary results
    Niesvizky, R.
    Bensinger, W.
    Vallone, M.
    Gutierrez, A.
    Kunkel, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)
    Krishnan, Amrita Y.
    Patel, Krina K.
    Hari, Parameswaran
    Jagannath, Sundar
    Niesvizky, Ruben
    Silbermann, Rebecca W.
    Berg, Deborah
    Lin, Jianchang
    Fedyk, Eric Robert
    Palumbo, Antonio
    Stockerl-Goldstein, Keith E.
    BLOOD, 2019, 134
  • [28] A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Multiple Myeloma
    Chakraborty, Rajshekhar
    Yan, Ying
    Royal, Mike
    BLOOD, 2021, 138
  • [29] Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma
    Kaufman, Jonathan L.
    Niesvizky, Ruben
    Stadtmauer, Edward A.
    Chanan-Khan, Asher
    Siegel, David
    Horne, Heather
    Wegener, William A.
    Goldenberg, David M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 163 (04) : 478 - 486
  • [30] Mezigdomide (MEZI) Plus Dexamethasone (DEX) in Relapsed/refractory Multiple Myeloma (RRMM): Results From the Dose-Expansion Phase of the CC-92480-MM-001 Trial
    Orlowski, Robert Z.
    Bahlis, Nizar J.
    Quach, Hang
    Popat, Rakesh
    Lonial, Sagar
    Kim, Kihyun
    Mateos, Maria-Victoria
    Pawlyn, Charlotte
    Ramasamy, Karthik
    Martinez-Lopez, Joaquin
    Casas-Aviles, Ignacio
    Spirli, Alessia
    Gong, Jing
    Amatangelo, Michael
    Katz, Jessica
    Maciag, Paulo
    Peluso, Teresa
    Richardson, Paul G.
    Trudel, Suzanne
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S492 - S493
12345